KACTUS is a biotechnology company serving global biopharma and diagnostics customers. We focus on commercial protein production for unmet needs in the drug development pipeline, including challenging recombinant proteins such as Claudin 18.2, MHC complexes, GPCR, CD20, and highly bioactive mRNA capping enzymes. Our goal is to deliver first-to-market innovative protein and antibody products. We also offer custom protein production including both research-grade and GMP-grade material. SAMS™ Technology Platform Our proprietary Structure Aided Design & Multiplex Screening (SAMS™) platform uses bioinformatics and 3D modeling to create vast search spaces for protein configurations. Expression conditions are optimized in vitro to identify settings that produce a natural protein configuration with bioactivity in multiple cell lines/settings. Quality KACTUS performs strict quality control testing on all our products including endotoxin levels. We also have facilities compatible with U.S. FDA cGMP guidelines to produce GMP-grade material. Our GMP-level partnerships are designed to provide you with routine bulk supply of material and supporting documentation to bring you from the R&D stage to commercial manufacturing and regulatory submission. In addition, our SAMS™ platform will assist in custom scientific optimization of your reagent.
External link for KACTUS
60 Hickory Dr
Waltham, Massachusetts 02451, US
Join us from November 8-9 at Booth #819 during #SITC2024 in Houston, TX! Connect with our team at the conference and explore how KACTUS' products and services—like our MHC monomers and tetramers—can help advance your research. #CancerImmunotherapy #PeptideMHCs #MHC #BiotechEvents #KACTUS #Biotech #InnovationInCancer
This content isn’t available here
Access this content and more in the LinkedIn app
🔬 Unlocking the Potential of MRGPRX2 in Allergy & Pain Management! 🔬 In recent years, MRGPRX2 has gained attention as a powerful player in allergy and pain pathways. As a receptor triggering mast cell degranulation and inflammatory responses, it’s implicated in hypersensitivity reactions, chronic urticaria, eczema, and even chronic pain. As the only only provider of off-the-shelf full-length mammalian-expressed MRGPRX2 protein, KACTUS supports researchers with ready-to-use nanodiscs, custom expression services, and more. Discover more in our latest blog! https://bit.ly/4fgUH9i #Biotech #MRGPRX2 #Allergy #PainManagement #KACTUS
📈Unlock the potential of your TCR research with KACTUS Bio’s custom Soluble TCR Expression Services! 📈 Our solutions include optimized TCR formats, engineering, and validation methods like SPR or ELISA, empowering you to advance your MHC and TCR studies. From TCR fusion proteins to personalized requests, we’re here to help you achieve accurate, reliable results. Elevate your next project with our expertise! Learn more about KACTUS Soluble TCR Expression Services: https://bit.ly/4dQ2pGB #TCR #MHC #Biotech #ResearchInnovation #SolubleTCR #Immunology #KactusBio
Stop by Booth #D40 to discover how KACTUS Bio’s advanced gene-editing tools and recombinant proteins can take your gene and cell therapy innovations to the next level before #ESGCT2024 ends 10/25. Whether you're seeking research-grade or GMP solutions, we’re here to support your breakthroughs! #GeneTherapy #CellTherapy #GMP #ResearchSolutions #VLP #InnovationInScience #KACTUSBio
🚨Exciting Update 🚨 Powered by KACTUS' AccuBase™ cytosine base editing enzyme, the NK therapy NK510 has achieved clinical trial approval, paving the way towards treating advanced solid tumors. This breakthrough therapy showcases the precision and minimal off-target effects of AccuBase™. As the exclusive supplier of AccuBase™, KACTUS continues to support gene editing advancements in cancer therapy. Learn more here:https://bit.ly/4dYAynp #BaseEditing #CancerTherapy #NKCells #GMP #Biotech #GeneEditing #KACTUSBio
💡 Industry Update: AvenCell Secures $112M for Next-Gen CAR-T Therapy AvenCell Therapeutics raised $112M in series B funding to advance its switchable CAR-T platform, enabling on/off control of CAR-T cells post-infusion for safer and more flexible treatments. Key programs AVC-101 (autologous CAR-T) and AVC-201 (CRISPR-engineered allogeneic CAR-T) target AML with early promising results. The funding round was led by Novo Holdings, along with other investors, showing strong confidence in next-gen cell therapy.🔗 https://bit.ly/4feMkeG #CAR-T #CellTherapy #Biotech #AML #CancerTherapy #Innovation #IndustryUpdate
We’re excited to head to Philadelphia for the Advanced Therapies 2024 Meeting! 📍 Location: Pennsylvania Convention Center, Philadelphia, PA 📅 Dates: November 12-13, 2024 📢 Join us at Advanced Therapies USA this November for in-depth sessions on the latest in cell and gene therapy, covering breakthroughs in gene editing, regenerative medicine, and manufacturing solutions. Check us out at booth #211 to talk about our gene and cell therapy products and grab some swag. Want to know more about Advanced Therapies 2024?🔗 Read more here: https://bit.ly/3UlGe4d #AT2024 #AdvancedTherapies2024 #GeneTherapy #CellTherapy #KACTUS #Biotech
⭐️Day 1 of the ESGCT 2024 Annual Congress in Rome is here! ⭐️ Come visit us at booth #D40 to explore how KACTUS can support your gene and cell therapy projects with our cutting-edge recombinant proteins and gene-editing tools. We look forward to networking with you and discussing how our GMP-grade and research-level innovative solutions can advance your research! #ESGCT2024 #GeneTherapy #CellTherapy #GMP #Research #VLP #KACTUSBio #Innovation #Biotech
🚨 Big news in the fight against RSV! 🚨 Merck has announced promising results for its experimental antibody drug, Clesrovimab, which reduced RSV incidence by 60% and hospitalizations by 84% in infants during Phase 2b/3 trials. With potential approval by the 2025-2026 RSV season, Clesrovimab could compete with Sanofi and AstraZeneca’s Beyfortus as a new option for preventing severe RSV in newborns, offering healthcare providers more tools to protect vulnerable populations. https://bit.ly/4dToHas #RSV #PediatricHealth #AntibodyTherapy #Biotech #Pharmaceuticals #Merck #HealthcareInnovation
AccuBase™ delivers precision in converting cytosine to thymine, driving impactful results across research, clinical, and therapeutic projects. Key Benefits: 🔬 Unmatched Accuracy: Edit with confidence—no double-strand breaks. ⭐️ GMP-Grade Quality: Designed for clinical use. 🎯 Versatility at Its Core: Suitable for research, clinical, and therapeutic use. Elevate your gene editing toolbox with AccuBase™ today! https://bit.ly/484xwN6 #Accubase #baseditor #GMP #GeneTherapy #Biotech #KACTUS